| Date | Time | Source | Announcement |
|---|---|---|---|
| 31 Oct 2000 | 07:00 AM | Second Interim Results 2000 | |
| 12 Jul 2000 | 02:24 PM | Interim Statement | |
| 19 Apr 2000 | 05:10 PM | Result of Open Offer | |
| 18 Apr 2000 | 05:48 PM | Result of EGM | |
| 18 Apr 2000 | 11:05 AM | Result of EGM | |
| 27 Mar 2000 | 07:01 AM | Restoration of Trading on AIM | |
| 24 Mar 2000 | 04:26 PM | Statement re Restoration of Dealing | |
| 24 Mar 2000 | 08:47 AM | Entitlement Details | |
| 24 Mar 2000 | 08:46 AM | Proposed Acquisition and Placing and Open Offer | |
| 17 Feb 2000 | 01:56 PM | Statement re Suspension of Trading | |
| 18 Jan 2000 | 03:55 PM | Statement re Share Price Movement | |
| 26 Nov 1999 | 02:31 PM | Insinger Townsley Appointed as Nominated Broker |
ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France.
ImmuPharma listed on AIM under the ticker IMM.
IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.
IMM share price listed in London at 1,190p in 2000.